Loading...
Thumbnail Image
Publication

A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver

Zheng, Chunwei
Liang, Shun-Qing
Liu, Bin
Liu, Pengpeng
Kwan, Suet-Yan
Wolfe, Scot A
Xue, Wen
Embargo Expiration Date
Abstract

Prime editor (PE) has tremendous promise for gene therapy. However, it remains a challenge to deliver PE (>6.3 kb) in vivo. Although PE can be split into two fragments and delivered using dual adeno-associated viruses (AAVs), choice of split sites within Cas9-which affects editing efficiency-is limited due to the large size of PE. Furthermore, overexpressing reverse transcriptase in mammalian cells might disrupt translation termination via its RNase H domain. Here, we developed a compact PE without the RNase H domain that showed editing comparable with full-length PE. With compact PE, we used a Cas9 split site (Glu 573) that supported robust editing in cells (up to 93% of full-length PE) and in mouse liver. We then demonstrated that split-cPE573 delivered by dual-AAV8 efficiently mediated a 3-bp TGA insertion in the Pcsk9 gene in mouse liver. Compact PE without the RNase H domain abolished its binding to peptidyl release factor 1 (eRF1) and mitigated the stop codon readthrough effect observed with full-length PE. This study identifies a compact PE with a flexible split design to advance utility of prime editing in vivo.

Source

Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022 Mar 2;30(3):1343-1351. doi: 10.1016/j.ymthe.2022.01.005. Epub 2022 Jan 5. PMID: 34998953; PMCID: PMC8899602.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.ymthe.2022.01.005
PubMed ID
34998953
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright © 2022 The American Society of Gene and Cell Therapy. Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0); Attribution-NonCommercial-NoDerivatives 4.0 International